A new class of antidiabetic drugs, the glucagon-like peptide-1 (GLP-1) receptor agonists such as exenatide, liraglutide (LIR), lixisenatide, and dulaglutide, are not only used therapeutically in diabetes patients, but some of them have already been shown to have powerful protective effects on cognitive function and can reverse or prevent neurodegeneration in animal models for AD (STZ-icv models: Xiong et al. 2013; Palleria et al. 2017; Zhou et al. 2019; the amyloid-ß-oligomers model: Batista et al. 2018; for review: Monti et al. 2022). This evidence concerns the gene GLP1R and Alzheimer disease.